Mesoblast Phase 3 Data Reveals a Single Injection of Rexlemestrocel-L Results in 2+ Years Pain Reduction, Opioid Sparing in Patients with Chronic Low Back Pain Due to Degenerative Disc Disease
Mesoblast announced results from a Phase 3 trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in patients with […]